Dose finding study of TAK-438 in patients with reflux esophagitis (phase II study)
Phase 2
- Conditions
- Reflux esophagitis
- Registration Number
- JPRN-jRCT2080220896
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Endoscopic diagnosis of grade A to D reflux esophagitis by LA classification at the start of the follow-up period (visit 1), etc.
Exclusion Criteria
1. Complications that may affect the esophagus, history of esophageal radiotherapy or cryotherapy, or presence of corrosive or physiochemical trauma
2. History of surgery for reflux esophagitis, dilation of esophageal stricture, or surgery of the stomach or duodenum
3. Acute upper gastrointestinal bleeding or active gastric or duodenal ulcer within 30 days prior to the start of the follow-up period, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method